Pagina 2 - Trattamento a Ramat Gan (Israele)

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Dr. Dorit Zilberman, MD, is a Senior Urologist at Sheba Medical Center. She is a pioneer of robotic and minimally invasive urologic surgery in Israel with over 20 years of experience. Her work focuses on urologic oncology, robotic and laparoscopic surgery, and endourology. She helped launch the da Vinci robotic surgery program at Sheba. Her expertise includes kidney, bladder, and prostate cancers, as well as laser lithotripsy for stones.

She completed advanced training in robotic laparoscopic surgery and endourology at Duke University Medical Center. She is a Senior Clinical Lecturer at Tel Aviv University. She has authored more than 160 scientific publications. She has received awards from the Israeli and American Urological Associations. She was listed in Forbes Israel Best Doctors in 2024. She is a member of the Israeli, American, and European Urological Associations and the Endourological Society.

Prof. Roy Mashiach, MD, is the Director of Gynecology at Sheba Medical Center. He is a leading expert in minimally invasive gynecologic surgery with over 30 years of experience. He focuses on laparoscopic and hysteroscopic hysterectomy. He also performs myoma removal, treats endometriosis, and offers fertility‑preserving procedures.

Recognition and roles: Named to Forbes Israel’s Best Doctors. Recipient of the Daniel F. Kott Award (AAGL). Chairman of the Israeli Society of Gynecological Endoscopy. Director of the Gynecologic Simulation Unit (M.S.R.). Clinical Associate Professor at Tel Aviv University. Training: MD from Tel Aviv University. Specialization at Lis Maternity & Women’s Hospital. Fellowship in Advanced Endoscopy at Université d’Auvergne.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Gil Raviv, MD, PhD, is Director of the Andrology Unit at Sheba Medical Center. He was listed among the Best Doctors in Israel by Forbes in 2024. He is a leading expert in male fertility, sexual medicine, and reconstructive urology.

His primary focus is male infertility and fertility preservation. He performs advanced semen analysis according to WHO standards. He carries out testicular sperm retrieval (TESE, TESA, MESA) and semen cryopreservation. He also provides comprehensive fertility diagnostics with histological analysis.

He is a Professor at Tel Aviv University. He trained in Siena, Rome, and Tel Aviv. He completed a fellowship in infertility and impotence at Erasme Hospital. He received advanced training in reconstructive urethral surgery in Ghent. He is a member of the European Association of Urology, the International Society for Sexual Medicine, and the Israeli Urological Association.

Professor Pnina Langevich is a rheumatologist and immunologist with over 40 years of experience. She leads the National Center for Rheumatology and Autoimmune Diseases at Sheba Medical Center. Forbes Israel has repeatedly named her among the country’s top doctors.

She is an expert in rheumatoid arthritis, osteoarthritis, joint diseases, systemic lupus erythematosus, scleroderma, and complex autoimmune disorders. She treats severe, treatment‑resistant cases using advanced diagnostics and personalized therapy.

She trained in rheumatology and internal medicine at Sheba. She combines patient care with research on new therapies. She served for 12 years as Vice President of the World Association of Rheumatologists. She is Editor‑in‑Chief of Lupus and a member of the Israeli Medical Association and the International Association of Rheumatologists.

Dr. Anton Wohl leads the Brain Tumors Unit at Sheba Medical Center (since 2026). He is a neurosurgeon specializing in neuro-oncology, brain tumor surgery, and stereotactic radiosurgery.

He performs complex tumor operations with intraoperative MRI and functional mapping. He also uses fluorescence guidance, neuronavigation, and awake craniotomy to help remove tumors safely and preserve function.

Accreditations: Israeli Board Certification in Neurosurgery; Israeli medical license; advanced international fellowships and training, including the Mayo Clinic (USA).

Research: author and co-author of peer-reviewed publications on glioblastoma, malignant brain tumors, radiosurgery, and experimental therapies.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.